NCT03952598
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 249 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial status changed: Suspended → Completed
- Primary and study completion dates changed from estimate of Dec 31, 2027 to Oct 28, 2026
- New version filed on ClinicalTrials.gov
- Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027v224
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Study on hold pending possible updates with the team.
- Enrollment target: estimated 270 to confirmed 42
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To monitor the quantitative levels of 2-hydroxyglutarate (2-HG) longitudinally in patients with IDH mutant gliomas via proton magnetic resonance spectroscopy (1H-MRS)
Timeframe: 5 years
Secondary (1)
Determine the utility of 2-HG detection by 1H-MRS to predict higher-grade transformation (HT) and hypermutator phenotype (HMP) by correlating the 2-HG level with pathological diagnosis and tumor mutational load of the tumor tissue at time of rec...
Arms and interventions
1/Arm 1Experimental
Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS) -- THIS ARM IS NOW CLOSED
2/Arm 2Experimental
Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS) and HP 13C pyruvate MRSI
3/Arms 3Experimental
Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS)
Drugs: HP 13C Pyruvate
Devices: 3T MRI scanner
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States